184 related articles for article (PubMed ID: 7773949)
1. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
van Hoff J; Grier HE; Douglass EC; Green DM
Cancer; 1995 Jun; 75(12):2966-70. PubMed ID: 7773949
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
3. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE
J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH
Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
Marina NM; Rodman JH; Murry DJ; Shema SJ; Bowman LC; Jones DP; Furman W; Meyer WH; Pratt CB
J Natl Cancer Inst; 1994 Apr; 86(7):544-8. PubMed ID: 8133538
[TBL] [Abstract][Full Text] [Related]
9. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR
Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510
[TBL] [Abstract][Full Text] [Related]
14. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study.
Kung FH; Pratt CB; Vega RA; Jaffe N; Strother D; Schwenn M; Nitschke R; Homans AC; Holbrook CT; Golembe B
Cancer; 1993 Mar; 71(5):1898-903. PubMed ID: 8448755
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of high-dose cisplatin, ifosfamide, and etoposide.
Perez EA; Sowray PC; Gardner SL; Gandara DR
Cancer Chemother Pharmacol; 1994; 34(4):331-4. PubMed ID: 8033300
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A
Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Lund B; Hansen OP; Hansen HH; Hansen M
Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
